keyboard_arrow_up

Europe Neuromodulation Devices Market is Estimated to Reach $2,310.6 Million by 2019 - MicroMarketMonitor

According to the new market research report " Europe Neuromodulation Devices Market by Procedure [Internal Stimulation (DBS, GES, SNS, SCS, VNS), and External Stimulation (TENS, TMS)], and by Geography – Analysis & Forecast to 2019 ", Based on procedure, the market is segmented into internal neurostimulation and external neurostimulation, wherein the internal neurostimulation segment dominates the market and is estimated to reach $2,001.5 million by 2019.

Neuromodulation treats a wide range of chronic and refractory disorders. The minimally invasive and noninvasive nature of this technique increases its adoptability and hence is considered as an outpatient procedure. Moreover, these therapies are reversible, that is, non-destructive. This allows physicians to cease treatment as and when required by removing the stimulating devices. Amongst one of the advanced technologies, neuromodulation treats a wide range of chronic and refractory disorders. The minimally invasive and noninvasive nature of this technique increases its adoptability and hence is considered as an outpatient procedure. Moreover, these therapies are reversible, that is, non-destructive, which allow physicians to cease treatment as and when required by removing the stimulating devices.


Based on internal stimulation, the market is categorized into spinal cord stimulation, deep brain stimulation vagus nerve stimulation, sacral nerve stimulation, and gastric electric stimulation. Among these, the spinal cord stimulation segment leads the market and is projected to reach $1,134.6 million by 2019. The external stimulation modality is categorized into transcutaneous electrical nerve stimulation (TENS) and transcranial magnetic stimulation (TMS); the TENS segment leads the market and is projected to reach $232.9 million by 2019.

The major players in the neuromodulation market include
  • Boston Scientific (U.S.), 
  • Cyberonics (U.S), 
  • Medtronic, Inc. (U.S.), 
  • Johnson & Johnson (U.S.), and 
  • St. Jude Medical Inc. (U.S.).


Growing prevalence of lower urinary tract diseases is creating growth opportunities for the neuromodulation market. According to a study by the British Journal of Urology International (BJUI), it was estimated that, by 2018, 2.3 billion individuals will be affected by at least one type of lower urinary tract symptoms (LUTS) such as overactive bladder (OAB) and urinary incontinence (UI). Globally, a rise of 18% to 19% is expected in the incidence of LUTS disorders.


Report Subscription:

MicroMarket Monitor produces exclusive market research reports, based on real-time data to provide better understanding of the dynamic market conditions of the Healthcare industry. The reports offer in-depth and complete analysis of the regional and country level marketplaces. The research reports for Healthcare industry are updated on quarterly basis and are easily available for purchase through annual subscriptions.   

http://www.micromarketmonitor.com/offerings/subscription

About MicroMarket Monitor:

MicroMarket Monitor identifies and attends to various unmet needs of different industrial verticals, which include value chain impact analysis. The company publishes about 12000 Market Research Reports on various Micro Markets across the world. The graphical nature and multidimensional analysis of these reports provide advanced Business Intelligence Tools to the clients in that particular target market.

Contact: 
Mr. Chandrasekhar K. 
UNIT no 802, Tower No. 7, SEZ
Magarpatta City, Hadapsar
Pune, Maharashtra 411013, 
India
Tel -  +1-888-502-0539 
sales@micromarketmonitor.com